Fineline Cube

Follow:
14446 Articles
Nutshell Therapeutics' NTS231 Clears FDA IND – First NRF2 Molecular Glue Degrader from China and Second Globally to Enter Clinical Development, Targeting KEAP1 to Block NRF2
CompanyDrug

Nutshell Therapeutics’ NTS231 Clears FDA IND – First NRF2 Molecular Glue Degrader from China and Second Globally to Enter Clinical Development, Targeting KEAP1 to Block NRF2

Simcere Pharmaceutical Files IND for SIM0688 – First B7‑H3/c‑Met Bispecific ADC to Enter Clinical Development
CompanyDrug

Simcere Pharmaceutical Files IND for SIM0688 – First B7‑H3/c‑Met Bispecific ADC to Enter Clinical Development

CDE Includes Beijing Toll Biotech's TollB‑001 Tablets in Rare Disease Pilot Scheme – Novel Oral TLR8 Inhibitor Targets Systemic Sclerosis with First Specific Treatment Potential
CompanyDrug

CDE Includes Beijing Toll Biotech’s TollB‑001 Tablets in Rare Disease Pilot Scheme – Novel Oral TLR8 Inhibitor Targets Systemic Sclerosis with First Specific Treatment Potential

CSPC Pharmaceutical Initiates Phase II Trial of SYH2069 – Novel Long‑Acting GLP‑1R/GIPR Dual Agonist with Dual‑Biased Activity for Adult Type 2 Diabetes
CompanyDrug

CSPC Pharmaceutical Initiates Phase II Trial of SYH2069 – Novel Long‑Acting GLP‑1R/GIPR Dual Agonist with Dual‑Biased Activity for Adult Type 2 Diabetes

GenScript Biotech Collaborates with Lilly TuneLab – Pairing Large‑Scale Wet‑Lab Validation with Eli Lilly's AI/ML Drug Discovery Platform
CompanyDeals

GenScript Biotech Collaborates with Lilly TuneLab – Pairing Large‑Scale Wet‑Lab Validation with Eli Lilly’s AI/ML Drug Discovery Platform

Novo Nordisk and Anthropic Announce AI Collaboration – Claude Science to Accelerate Drug Discovery and AI‑Driven Software Development
CompanyDeals

Novo Nordisk and Anthropic Announce AI Collaboration – Claude Science to Accelerate Drug Discovery and AI‑Driven Software Development

NMPA Grants Priority Review to Everest Medicines' Manufacturing‑Transfer NDA for VELSIPITY (Etrasimod) – Localizing Production of Its Approved Ulcerative Colitis Therapy in China
CompanyDrug

NMPA Grants Priority Review to Everest Medicines’ Manufacturing‑Transfer NDA for VELSIPITY (Etrasimod) – Localizing Production of Its Approved Ulcerative Colitis Therapy in China

Novartis Exercises Exclusive Option to Acquire Global Rights to Sironax Brain Delivery Platform – USD 125 Million Transaction Targets Blood‑Brain Barrier Breakthrough for CNS Diseases
CompanyDeals

Novartis Exercises Exclusive Option to Acquire Sironax Brain Delivery Platform in USD 125 Million Transaction

China Resources Pharmaceutical and Sino Biopharmaceutical Sign Strategic Pact Spanning R&D, Distribution and DTP Channels Toward RMB 10 Billion Target
CompanyDeals

China Resources Pharmaceutical and Sino Biopharmaceutical Sign Strategic Pact Spanning R&D, Distribution and DTP Channels Toward RMB 10 Billion Target

Tempest Therapeutics Secures Exclusive Option to License Senlang's CD7‑Targeted In Vivo CAR‑T Platform – Lead Bispecific BCMA/GPRC5D Candidate in Phase I for Relapsed/Refractory Multiple Myeloma
CompanyDeals

Tempest Therapeutics Secures Exclusive Option to License Senlang’s CD7‑Targeted In Vivo CAR‑T Platform – Lead Bispecific BCMA/GPRC5D Candidate in Phase I for Relapsed/Refractory Multiple Myeloma

ACROBiosystems and MediumBank Forge Strategic Partnership on AI‑Designed Proteins – Closed‑Loop Program Targets Thermostable bFGF and High‑Activity Cytokines for Cell Culture Media
CompanyDeals

ACROBiosystems and MediumBank Forge Strategic Partnership on AI‑Designed Proteins – Closed‑Loop Program Targets Thermostable bFGF and High‑Activity Cytokines for Cell Culture Media

NMPA Accepts Qilu Pharmaceutical's Marketing Application for Meropenem/Pralurbactam for Injection – First Independently Developed Novel β‑Lactamase Inhibitor Combination in China for cIAI
CompanyDrug

NMPA Accepts Qilu Pharmaceutical’s Marketing Application for Meropenem/Pralurbactam for Injection – First Independently Developed Novel β‑Lactamase Inhibitor Combination in China for cIAI